GE HealthCare has purchased full ownership of Japanese radiopharmaceutical developer Nihon Medi-Physics (NMP) from Sumitomo Chemical.
The vendor had previously held a 50% stake in NMP, which has a product portfolio that includes GE HealthCare’s Vizamyl amyloid visualization radiotracer, DaTSCAN agent for Parkinson’s diagnosis, and Myoview SPECT myocardial perfusion imaging agent. NMP also provides research and development, including nonclinical and clinical development of radiotracers and theranostics research.
The deal, which was initially announced at RSNA 2024, is expected to be neutral to GE HealthCare’s adjusted earnings per share in the first year and accretive thereafter, according to the vendor.